{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', '11.2.3.', 'Weight/Body Mass Index', 'For determination of height and weight, subjects should be clothed with shoes removed.', 'BMI should be calculated using the following formula:', 'BMI = weight (kg)/height (m)\u00b2', 'BMI and height are only to be captured at the screening visit. Adolescents will also have height', 'captured at Weeks 48, 96, and 144.', '11.2.4.', '12-lead Electrocardiograms', 'A standard bedside or routine 12-lead ECG machine that calculates heart rate and measures the', 'PR, QRS, QT, RR, and QTc (QTcF) intervals will be utilized. Prior to obtaining an ECG,', 'subjects should rest quietly in a supine position for at least 10 minutes.', 'Qualified site personnel should review the ECGs and automated findings in real-time for gross', 'abnormalities and interval measurements of concern (absolute readings and for postbaseline', 'ECGs, a change from baseline). For all ECGs, the clinical interpretation of the ECG and', 'calculated QTcF (including adjudication of any automated measurements or diagnoses) should', 'be recorded directly on a hard copy of the ECGs. Copies of the ECGs may be requested by the', 'Sponsor. All subject identifiers will be masked prior to provision to the Sponsor.', 'Baseline (predose) and Week 24 ECGs will be obtained in triplicate (ie, 3 separate readings', 'taken at 1- - to 5-minute intervals) with baseline values calculated from an average of the', '3 readings. All other ECGs will be single assessments.', 'An ECG should be repeated for a change from baseline in QTcF > 60 msec or a QTcF interval', '> 500 msec.', '11.2.5.', 'Vital Signs', 'Blood pressure (systolic and diastolic) and pulse rate should be taken after the subject has rested', 'in the supine position for at least 5 minutes. Blood pressure measurements must be obtained with', \"an appropriate cuff size and with the subject's arm supported at the level of the heart. It is\", 'acceptable to obtain a pulse rate from the blood pressure or ECG machine. Temperature and', 'respiratory rate will be captured at Screening, Baseline, and Week 24 only.', '11.2.6.', 'Clinical Laboratory Evaluations', 'Blood and urine samples will be obtained per the schedule of events. Individual laboratory tests', 'to be performed are provided in Table 5.', 'All laboratory samples will be collected using kit supplies provided by the central laboratory,', 'which will also analyze all samples, the possible exception of Week 2 and Week 26 liver', 'function assessments which may be drawn and resulted locally. If results are obtained from both', 'central and local laboratories for the same assessments at a single study time point, only the', 'central laboratory results will be used for study purposes. Additionally, urine pregnancy tests', 'will be provided by the central lab but will be analyzed at the clinical site. A laboratory reference', 'manual will be provided to the site detailing kit contents, reordering instructions, subject fasting', 'requirements (if any), sample collection, handling, storage, and shipment.', '72']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'Results from the laboratory values should be reviewed as received by the Investigator. Evidence', 'of this review should be provided in the source records and may include printing of the', 'laboratory reports with a signature attesting to a review. For out-of-range laboratory findings, the', 'interpretation of clinically significant or not clinically significant should be denoted in the source', 'records. Clinically significant laboratory findings in the opinion of the Investigator should be', 'recorded as an AE and handled as described in Section 12.1.', '73']\n\n###\n\n", "completion": "END"}